EUVIMEDScopri EUVIMED
Randomisierte kontrollierte Studie

Randomised controlled trial of Jiandu granule in preventing chemoradiotherapy‐induced oral mucositis

Huakang Li, Jianlong Ke, Xiaoyan Wang, Bo Xu, Qiang Li, Ziliang Wu, Yue Wang, Bing Lin iD

Oral Diseases · 2024

DOI: 10.1111/odi.14745 ↗

At a glance

Randomisierte kontrollierte Studie in Oral Diseases, 2024. Written by Huakang Li and 7 co-authors. Institution: Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. Major MEDLINE topics: Drugs, Chinese Herbal, Chemoradiotherapy, Stomatitis, Nasopharyngeal Neoplasms. Cited 2 times so far (Crossref); 30 references. Funded by: Sichuan Provincial Science and Technology Department Project.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Objective

This clinical trial aimed to evaluate the efficacy and safety of Jiandu granule, a Chinese herbal medicine formula, for preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy. Materials and Methods A single‐centre, open‐label, randomised controlled trial was conducted, enrolling 138 patients with locally advanced nasopharyngeal carcinoma. Patients were randomly allocated to either the experimental group ( n = 69) or the control group ( n = 69). Both groups received concurrent chemoradiotherapy and standard care for oral mucositis, with the experimental group additionally receiving Jiandu granule intervention. The primary outcome was the incidence of severe oral mucositis (grade III to IV).

Results

In the full‐analysis set, severe oral mucositis occurred in 14 of 69 (20.3%) patients in the experimental group and 31 of 69 (44.9%) patients in the control group (absolute risk reduction: 24.6%; relative risk reduction: 54.8%; p = 0.002; number needed to treat: 4). Jiandu granule was associated with mild/moderate gastrointestinal reactions, with an overall incidence of 5.9%.

Conclusion

Jiandu granule reduced the incidence of severe oral mucositis in nasopharyngeal carcinoma patients during concurrent chemoradiotherapy and had an acceptable safety profile.

Subjects

MeSH terms (MEDLINE)

Drugs, Chinese HerbalChemoradiotherapyStomatitisNasopharyngeal NeoplasmsHumansMaleFemaleMiddle AgedAdultNasopharyngeal CarcinomaAged

Author keywords

Chinese herbal medicine formulaconcurrent chemoradiotherapynasopharyngeal carcinomaoral mucositisrandomised controlled trialtraditional Chinese medicine

Substances

Drugs, Chinese Herbal

Authors and institutions

  • Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • The Traditional Chinese Medicine Hospital of Longquanyi, Chengdu, China.
  • Sichuan Cancer Hospital, Chengdu, China.

ORCID profiles: Bing Lin

Funding

  • Sichuan Provincial Science and Technology Department Project

Cite

APA

Li, H., Ke, J., Wang, X., Xu, B., Li, Q., Wu, Z., Wang, Y., & Lin, B. (2024). Randomised controlled trial of Jiandu granule in preventing chemoradiotherapy‐induced oral mucositis. Oral Diseases. https://doi.org/10.1111/odi.14745

Vancouver

Li H, Ke J, Wang X, Xu B, Li Q, Wu Z, et al. Randomised controlled trial of Jiandu granule in preventing chemoradiotherapy‐induced oral mucositis. Oral Diseases. 2024. doi:10.1111/odi.14745

BibTeX
@article{Li2024,
  author = {Li, Huakang and Ke, Jianlong and Wang, Xiaoyan and Xu, Bo and Li, Qiang and Wu, Ziliang and Wang, Yue and Lin, Bing},
  title = {Randomised controlled trial of Jiandu granule in preventing chemoradiotherapy‐induced oral mucositis},
  journal = {Oral Diseases},
  year = {2024},
  doi = {10.1111/odi.14745}
}
Start for free →